Compare Howmet Aerospace Inc (HWM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs BIO-TECHNE Corp — how do they compare? Howmet Aerospace Inc trades at $282.13 (market cap $113.14B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Howmet Aerospace Inc is far larger — about 10.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| HWM | TECH | |
|---|---|---|
Market Cap | $113.14B | $11.24B |
Sector | Industrials | Health |
52-Week High | $291.28 | $72.29 |
52-Week Low | $171.00 | $43.31 |
Enterprise Value | $117.24B | $11.32B |
Dividend Yield | 0.2% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $281.88, down 2.71% on the day, but maintains strong technical momentum with a bullish moving average signal. The company continues to deliver impressive financial results, beating earnings estimates for three consecutive quarters with Q2 2026 EPS of $1.33 exceeding expectations. Recent news highlights robust aerospace and defense demand driving revenue growth of 24% year-over-year and prompting upward guidance revisions.
The outlook remains positive with 84% analyst buy ratings and a $334.63 consensus price target representing 19% upside potential. Key risks include execution of capacity expansion plans and potential supply chain constraints. Strong cash flow generation and institutional confidence support the bullish thesis for continued aerospace sector outperformance.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
